Incannex Healthcare (IXHL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Oct, 2026Executive summary
Annual Meeting set for Dec. 17, 2026 at 10:00 a.m. GST, held virtually by live audio webcast; stockholders may vote and submit meeting-related questions online.
Board recommends FOR two Class III director nominees and ratification of Grant Thornton Audit Pty Ltd for FY ending June 30, 2027.
Voting matters and shareholder proposals
Proposal 1: elect Joel Latham and Troy Valentine to three-year terms ending in 2029; election requires a plurality of votes cast.
Proposal 2: ratify Grant Thornton’s appointment; approval requires a majority of voting power present or represented by proxy and entitled to vote.
Record date Oct. 22, 2026; 12,544,627 common shares outstanding, with one vote per share; quorum is one-third of voting power outstanding and entitled to vote.
Stockholders may change or revoke a proxy before the meeting; preliminary results are to be announced at the meeting, with results filed on Form 8-K within four business days.
Rule 14a-8 proposals for the 2027 meeting are due by July 5, 2027; bylaw proposals and director nominations have an Aug. 19–Sept. 18, 2027 notice window, subject to meeting-date changes.
Board of directors and corporate governance
Five-member classified board; Joel Latham is CEO and director, while Troy Valentine is non-executive Chair; nominees Latham and Valentine are proposed for terms through 2029.
Robert Clark, Peter Widdows and Dr. George Anastassov are independent; Widdows chairs the audit committee, with Clark and Anastassov as members.
Audit committee met once and compensation committee twice in FY ended June 30, 2026; no director attended fewer than 75% of applicable board and committee meetings.
Compensation committee uses Compensia as independent adviser; CEO is excluded from decisions on his compensation, and executives do not set their own pay.
Independent directors oversee director selection and nominations; the board reviews composition annually and seeks diversity of occupational and personal backgrounds.
Latest events from Incannex Healthcare
- DREAMzz dosing advanced as quarterly losses narrowed, but a control weakness persists.IXHL
Q1 2027 - Two director elections and auditor ratification headline the Dec. 17 virtual meeting.IXHL
Proxy filing - Clinical investment grew; $14.55m cash was forecast to fund operations through Dec. 2024.IXHL
Q2 2024 - Net loss improved to $19.3M, cash rose to $67.7M, and lead clinical programs advanced.IXHL
Q4 2026 - Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases.IXHL
Q3 2026 - Late-stage oral therapies for OSA, GAD, and RA show strong efficacy and safety in Phase 2 trials.IXHL
Investor presentation - Net loss reached $12.9M, cash rose to $68.9M, and 3.1M shares were repurchased.IXHL
Q2 2026 - Annual meeting adjourned and rescheduled due to auditor proposal classification issue.IXHL
Proxy Filing - Net loss widened to $5.4M as cash fell to $3.6M, with new financings offsetting going concern risks.IXHL
Q1 2025